| Literature DB >> 32220010 |
Márton Tokodi1, Endre Németh2, Bálint K Lakatos1, Erika Kispál1, Zoltán Tősér3, Levente Staub3, Kristóf Rácz2, Ádám Soltész2, Szabolcs Szigeti2, Tamás Varga2, János Gál2, Béla Merkely1, Attila Kovács1.
Abstract
AIMS: The PREPARE-MVR study (PRediction of Early PostoperAtive Right vEntricular failure in Mitral Valve Replacement/Repair patients) sought to investigate the alterations of right ventricular (RV) contraction pattern in patients undergoing mitral valve replacement/repair (MVR) and to explore the associations between pre-operative RV mechanics and early post-operative RV dysfunction (RVD). METHODS ANDEntities:
Keywords: 3D echocardiography; Mitral valve regurgitation; Mitral valve surgery; Right ventricle; Right ventricular dysfunction
Mesh:
Year: 2020 PMID: 32220010 PMCID: PMC7261576 DOI: 10.1002/ehf2.12682
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Figure 1Outline of the study protocol. FU, follow‐up; ICU, intensive care unit; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MVR, mitral valve replacement/repair; PAC, pulmonary artery catheterization; RVEF, right ventricular ejection fraction.
Echocardiographic characteristics of healthy controls and patients undergoing mitral valve replacement/repair
| Controls | Pre‐operative | Post‐operative | 6‐month FU | Overall | |
|---|---|---|---|---|---|
|
|
|
|
| ||
| Left ventricle | |||||
| 3D LVMi (g/m2) | 62 [56–67] | 95 [78–112] | 88 [73–105] | 67 [60–75] | <0.001 |
| 3D LVEDVi (mL/m2) | 59 [52–64] | 91 [74–109] | 74 [65–90] | 61 [53–70] | <0.001 |
| 3D LVESVi (mL/m2) | 23 [21–26] | 34 [27–40] | 38 [29–45] | 25 [23–29] | <0.001 |
| 3D LVEF (%) | 61 [59–62] | 63 [61–65] | 51 [46–57] | 58 [56–61] | <0.001 |
| 3D LVGLS (%) | −22 [−23 to −19] | −22 [−24 to −20] | −16 [−18 to −13] | −18 [−20 to −16] | <0.001 |
| 3D LVGCS (%) | −31 [−33 to −27] | −32 [−34 to −29] | −24 [−28 to −20] | −29 [−31 to −27] | <0.001 |
| Right ventricle | |||||
| RV basal diameter (mm) | 32 [29–33] | 35 [30–37] | 36 [32–38] | 34 [31–36] | 0.139 |
| RV length (mm) | 81 [74–86] | 86 [81–93] | 82 [76–92] | 77 [73–83] | <0.001 |
| TAPSE (mm) | 24 [21–26] | 26 [23–30] | 13 [11–15] | 17 [13–18] | <0.001 |
| RV S′ (cm/s) | 15 [14–17] | 14 [13–16] | 9 [7–11] | 10 [8–12] | <0.001 |
| RV 2D free wall LS (%) | −22 [−25 to −19] | −27 [−32 to −22] | −19 [−23 to −17] | −28 [−32 to −23] | <0.001 |
| FAC (%) | 54 [50–58] | 39 [34–47] | 41 [35–46] | 47 [42–52] | <0.001 |
| 3D RVEDVi (mL/m2) | 57 [51–60] | 66 [58–82] | 66 [55–82] | 60 [53–70] | <0.001 |
| 3D RVESVi (mL/m2) | 21 [20–24] | 31 [28–42] | 32 [28–44] | 27 [24–37] | <0.001 |
| 3D RVEF (%) | 61 [58–65] | 52 [50–55] | 51 [46–54] | 53 [49–57] | 0.005 |
| LEF (%) | 29 [26–31] | 28 [23–32] | 17 [12–20] | 23 [20–27] | <0.001 |
| REF (%) | 26 [21–31] | 16 [12–23] | 23 [17–27] | 21 [19–27] | 0.032 |
| LEFi | 0.48 [0.42–0.51] | 0.53 [0.47–0.58] | 0.33 [0.28–0.43] | 0.44 [0.38–0.50] | <0.001 |
| REFi | 0.43 [0.37–0.48] | 0.33 [0.22–0.42] | 0.46 [0.37–0.51] | 0.41 [0.36–0.49] | 0.008 |
| 3D RVGLS (%) | −24 [−26 to −21] | −28 [−33 to −22] | −19 [−22 to −15] | −24 [−28 to −21] | <0.001 |
| 3D RVGCS (%) | −24 [−28 to −22] | −24 [−27 to −19] | −26 [−28 to −21] | −25 [−28 to −19] | 0.956 |
FAC, fractional area change; FU, follow‐up; LEF, longitudinal ejection fraction; LEFi, longitudinal ejection fraction index; LVEDVi, left ventricular end‐diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end‐systolic volume index; LVGCS, left ventricular global circumferential strain; LVGLS, left ventricular global longitudinal strain; LVMi, left ventricular mass index; REF, radial ejection fraction; REFi, radial ejection fraction index; RV, right ventricle; RVEDVi, right ventricular end‐diastolic volume; RVEF, right ventricular ejection fraction; RVESVi, right ventricular end‐systolic volume; RVGCS, right ventricular global circumferential strain; RVGLS, right ventricular global longitudinal strain; TAPSE, tricuspid annular plane systolic excursion.
P < 0.05 vs. healthy controls, unpaired Student's t‐test or Mann–Whitney U‐test.
P < 0.05 pre‐operative vs. post‐operative.
P < 0.05 pre‐operative vs. 6‐month follow‐up.
P < 0.05 post‐operative vs. 6‐month follow‐up.
Multiple groups (pre‐operative vs. post‐operative vs. 6‐month follow‐up) were compared using Friedman test with Nemenyi post hoc test, or one‐way repeated measures ANOVA with Tukey's post hoc test (the last column is the overall P‐value of ANOVA or Friedman test).
Figure 2Contribution of longitudinal and radial contractions to global systolic RV function in healthy controls and patients undergoing MVR. Before surgery, the longitudinal shortening was the major contributor to global RV function, whereas after MVR, the radial contraction became the dominant component. However, this shift was temporary as 6 months later the contribution of the two components equalized, and the contraction pattern became similar to healthy controls'. * P < 0.05, paired Student's t‐test or paired Wilcoxon test. FU, follow‐up; LEFi, longitudinal ejection fraction index; MVR, mitral valve replacement/repair; REFi, radial ejection fraction index; RV, right ventricle.
Figure 3RV mechanics in healthy controls and patients undergoing surgical treatment of severe primary MR: representative cases. By decomposing the motion of the 3D RV model, the different wall motion components can be quantified separately. The green mesh represents the end‐diastolic volume, and the blue surface is the end‐systolic volume of the RV. In the healthy subject, the longitudinal and radial motion contributed equally to global RV function (LEFi vs. REFi: 0.48 vs. 0.44). In the patient with severe MR, the pre‐operatively observed longitudinal dominance (LEFi vs. REFi: 0.54 vs. 0.29) shifted to radial dominance (LEFi vs. REFi: 0.39 vs. 0.51). However, this shift was temporary as 6 months later the contribution of the two components equalized, and the contraction pattern became similar to healthy control's (LEFi vs. REFi: 0.46 vs. 0.43). FU, follow‐up; LEFi, longitudinal ejection fraction index; MR, mitral regurgitation; REFi, radial ejection fraction index; RV, right ventricle.
Comparison of patients with and without post‐operative right ventricular dysfunction
|
No post‐operative RVD
|
Post‐operative RVD
|
| |
|---|---|---|---|
| Demographics | |||
| Age (years) | 67 [54–70] | 64 [61–69] | 0.666 |
| Male | 20 (71) | 9 (64) | 0.729 |
| BMI (kg/m2) | 27 [24–30] | 25 [24–27] | 0.270 |
| HTN | 21 (75) | 10 (71) | 1.000 |
| HLD | 15 (54) | 5 (36) | 0.338 |
| DM | 5 (18) | 0 (0) | 0.151 |
| CKD (GFR < 60 mL/min/1.73 m2) | 1 (4) | 1 (7) | 1.000 |
| Chronic anaemia | 1 (4) | 4 (29) | 0.035 |
| Tobacco abuse | 7 (25) | 2 (14) | 0.692 |
| History of atrial fibrillation (any type) | 7 (25) | 3 (21) | 1.000 |
| NYHA | |||
| I | 8 (29) | 1 (7) | |
| II | 5 (18) | 4 (29) | |
| III | 15 (54) | 9 (64) | |
| IV | 0 (0) | 0 (0) | 0.340 |
| EUROSCORE II (%) | 1.60 [1.08–2.26] | 1.21 [0.88–1.76] | 0.379 |
| Pre‐operative echocardiogram | |||
| 3D LAESVi (mL/m2) | 66 [53–81] | 54 [44–78] | 0.470 |
| 3D LVMi (g/m2) | 108 [84–114] | 80 [76–91] | 0.020 |
| 3D LVEDVi (mL/m2) | 97 [81–111] | 74 [67–95] | 0.075 |
| 3D LVESVi (mL/m2) | 37 [29–41] | 31 [25–33] | 0.063 |
| 3D LVEF (%) | 63 [62–65] | 63 [60–65] | 0.576 |
| 3D LVGLS (%) | −23 [−24 to −21] | −21 [−22 to −19] | 0.357 |
| 3D LVGCS (%) | −32 [−33 to −29] | −32 [−35 to −30] | 0.988 |
| RV basal diameter (mm) | 35 [33–38] | 30 [28–35] | 0.012 |
| RV length (mm) | 86 [82–94] | 84 [77–91] | 0.485 |
| TAPSE (mm) | 26 [23–30] | 26 [23–28] | 0.965 |
| RV S′ (cm/s) | 14 [13–17] | 13 [12–15] | 0.143 |
| RV 2D free wall LS (%) | −26 [−29 to −20] | −31 [−35 to −25] | 0.031 |
| Fractional area change (%) | 38 [34–43] | 44 [38–49] | 0.143 |
| 3D RVEDVi (mL/m2) | 73 [62–88] | 60 [54–70] | 0.071 |
| 3D RVESVi (mL/m2) | 35 [29–47] | 29 [24–33] | 0.023 |
| 3D RVEF (%) | 52 [49–55] | 53 [52–55] | 0.189 |
| LEF (%) | 26 [21–30] | 31 [27–34] | 0.006 |
| REF (%) | 18 [12–24] | 15 [12–20] | 0.416 |
| LEFi | 0.49 [0.46–0.55] | 0.57 [0.53–0.63] | 0.011 |
| REFi | 0.35 [0.22–0.43] | 0.29 [0.24–0.37] | 0.141 |
| 3D RVGLS (%) | −27 [−32 to −21] | −35 [−39 to −29] | 0.007 |
| 3D RVGCS (%) | −25 [−29 to −21] | −21 [−25 to −19] | 0.531 |
| Intraoperative parameters | |||
| Type of surgery | |||
| Annuloplasty or valvuloplasty | 9 (32) | 7 (50) | |
| Biological valve implantation | 7 (25) | 2 (14) | |
| Mechanical valve implantation | 12 (43) | 5 (36) | 0.536 |
| De Vega annuloplasty | 8 (29) | 1 (7) | 0.230 |
| Cross‐clamp time (min) | 79 [69–87] | 71 [61–88] | 0.584 |
| Cardiopulmonary bypass time (min) | 100 [93–112] | 98 [82–104] | 0.461 |
BMI, body mass index; CKD, chronic kidney disease; DM, diabetes mellitus; FAC, fractional area change; GFR, glomerular filtration rate; HLD, hyperlipidaemia; HTN, hypertension; LAESVi, left atrial end‐systolic volume index; LEF, longitudinal ejection fraction; LEFi, longitudinal ejection fraction index; LVEDVi, left ventricular end‐diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end‐systolic volume index; LVGCS, left ventricular global circumferential strain; LVGLS, left ventricular global longitudinal strain; LVMi, left ventricular mass index; NYHA, New York Heart Association; REF, radial ejection fraction; REFi, radial ejection fraction index; RV, right ventricle; RVD, right ventricular dysfunction; RVEDVi, right ventricular end‐diastolic volume; RVEF, right ventricular ejection fraction; RVESVi, right ventricular end‐systolic volume; RVGCS, right ventricular global circumferential strain; RVGLS, right ventricular global longitudinal strain; TAPSE, tricuspid annular plane systolic excursion.
Statistical test: unpaired Student's t‐test or Mann–Whitney U‐test.
Chronic anaemia was defined as haemoglobin concentration < 120 g/L in women or <130 g/L in men.
Intra‐observer and inter‐observer variability of key 3D echocardiographic parameters
| Intra‐observer variability (95% confidence interval) | Inter‐observer variability (95% confidence interval) | |
|---|---|---|
| 3D LAESV | 0.970 (0.913–0.990) | 0.964 (0.875–0.990) |
| 3D LVEDV | 0.982 (0.950–0.994) | 0.971 (0.921–0.990) |
| 3D LVESV | 0.981 (0.950–0.992) | 0.963 (0.901–0.987) |
| 3D RVEDV | 0.992 (0.978–1.000) | 0.954 (0.879–0.983) |
| 3D RVESV | 0.977 (0.936–0.992) | 0.900 (0.758–0.961) |
| 3D RVESV after decomposition, longitudinal motion only | 0.895 (0.728–0.961) | 0.856 (0.673–0.940) |
| 3D RVESV after decomposition, radial motion only | 0.933 (0.823–0.976) | 0.896 (0.756–0.958) |
LAESV, left atrial end‐systolic volume; LVEDV, left ventricular end‐diastolic volume; LVESV, left ventricular end‐systolic volume; RVEDV, right ventricular end‐diastolic volume; RVESV, right ventricular end‐systolic volume.
Statistical test: Lin's concordance correlation.